UK Markets close in 3 hrs 48 mins
  • FTSE 100

    7,018.98
    -8.50 (-0.12%)
     
  • FTSE 250

    23,750.03
    +117.19 (+0.50%)
     
  • AIM

    1,279.89
    +7.75 (+0.61%)
     
  • GBP/EUR

    1.1707
    -0.0011 (-0.10%)
     
  • GBP/USD

    1.3794
    -0.0003 (-0.0207%)
     
  • BTC-GBP

    34,444.73
    -487.43 (-1.40%)
     
  • CMC Crypto 200

    1,205.17
    -28.12 (-2.28%)
     
  • S&P 500

    4,473.75
    -6.95 (-0.16%)
     
  • DOW

    34,751.32
    -63.07 (-0.18%)
     
  • CRUDE OIL

    72.14
    -0.47 (-0.65%)
     
  • GOLD FUTURES

    1,760.00
    +3.30 (+0.19%)
     
  • NIKKEI 225

    30,500.05
    +176.71 (+0.58%)
     
  • HANG SENG

    24,920.76
    +252.91 (+1.03%)
     
  • DAX

    15,579.20
    -72.55 (-0.46%)
     
  • CAC 40

    6,609.34
    -13.25 (-0.20%)
     

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement

·1-min read

Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models

DUBLIN & SHIZUOKA, Japan, July 27, 2021--(BUSINESS WIRE)--ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, today announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

Japan SLC supports research organizations by providing animal models from its varied portfolio, including outbred, inbred, immunodeficient, congenic, hybrid, disease models and transgenic. The addition of CRISPR/Cas9 technology to the company’s toolbox will enable the expansion of its offering.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

"We are proud to add Japan SLC to our growing list of partners in Japan applying CRISPR/Cas9 technology to its service offerings," said Eric Rhodes, CEO of ERS Genomics. "Japan SLC’s animal production and supply are of high quality, and we are very pleased that it has chosen to license CRISPR/Cas9 technology through ERS Genomics."

"Our production and supply of laboratory animals will benefit greatly through the use of the revolutionary CRISPR/Cas9 technology," commented Hirotaka Takagi, President, Japan SLC. "We are very excited to sign this licensing agreement with ERS Genomics which will enable us to produce CRISPR-edited mouse and rat models."

Financial details of the agreement are not disclosed.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005813/en/

Contacts

Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting